Merck KGaA (OTCMKTS:MKKGY) Lowered to Hold Rating by UBS Group

UBS Group lowered shares of Merck KGaA (OTCMKTS:MKKGY) from a strong-buy rating to a hold rating in a report issued on Thursday,Zacks.com reports.

MKKGY has been the subject of a number of other reports. Zacks Research upgraded shares of Merck KGaA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 22nd. HSBC upgraded Merck KGaA to a “hold” rating in a report on Monday, July 6th. Finally, Jefferies Financial Group started coverage on Merck KGaA in a report on Tuesday, May 26th. They issued a “hold” rating for the company. Six investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, Merck KGaA presently has an average rating of “Hold”.

Merck KGaA Price Performance

Shares of Merck KGaA stock opened at $32.24 on Thursday. The firm has a market cap of $20.83 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 2.62 and a beta of 0.98. Merck KGaA has a 12-month low of $23.73 and a 12-month high of $34.19. The company has a quick ratio of 1.00, a current ratio of 1.51 and a debt-to-equity ratio of 0.36. The company’s fifty day simple moving average is $32.23 and its two-hundred day simple moving average is $29.36.

About Merck KGaA

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.